Data / Form D filings / Pelage Pharmaceuticals, Inc.
Pelage Pharmaceuticals, Inc.: Form D filings
Pelage Pharmaceuticals, Inc., a pharmaceuticals company in Los Angeles, CA, filed 3 Form D notices with the SEC between 2023 and 2025. The latest, on November 24, 2025, reports $120 million sold of a $120 million offering to 5 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 907 WESTWOOD BLVD #384, Los Angeles, CA, 90024
- Phone
- (949) 244-9904
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1982875
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Nov 24, 2025 | New notice | $119,999,987 | $119,999,987 | 5 | Sep 18, 2025 | sec.gov | |
| Aug 23, 2024 | New notice | $13,999,994 | $13,999,994 | 6 | Aug 12, 2024 | sec.gov | |
| Jun 28, 2023 | New notice | $16,749,994 | $16,749,994 | 6 | Jun 20, 2023 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Cathy Edward Friedman | Director | |
| Nathan Edward Wheeler | Executive Officer | |
| William Edward Lowry | Executive Officer, Director | |
| Christina Edward Weng | Executive Officer | |
| Daniel Gil | Executive Officer, Director | |
| Richard Edward Heyman | Director |
Other pharmaceuticals companies in California that filed recently
- Anvion Bio, Inc. $100,000 · Oct 7, 2026
- Aqur Biosciences, Inc. $1.5 million · Sep 18, 2026
- BTB Therapeutics, Inc. $8.9 million · Aug 12, 2026
Every Form D from the week of Nov 24, 2025 · All recent filings in California · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what Pelage Pharmaceuticals, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.